Novo Nordisk A/S (ADR) (NYSE:NVO)

CAPS Rating: 4 out of 5

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

Recs

0
Player Avatar Anjaconda (70.37) Submitted: 10/27/2011 5:05:39 PM : Outperform Start Price: $109.24 NVO Score: +25.51

Diabetes products - this is where it's at. Look at the stats and predictions for the disease in the coming years!

Featured Broker Partners


Advertisement